FDA Pulls Approval of Niacin, Fibrate in Combo with StatinsFDA Pulls Approval of Niacin, Fibrate in Combo with Statins

The agency is withdrawing approvals of two drugs for combining with statins in treating dyslipidemia; they are already seldom used with statins following trials years ago failing to show much benefit. News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news

Related Links:

Conclusion: It was concluded that LA is a safe and effective technique that could be considered in the management of hypercholesterolemia and future risk. Randomized control trials would further support a role for LA as a therapeutic option.Blood Purif
Source: Blood Purification - Category: Hematology Source Type: research
(Natural News) One out of every five Americans has been convinced to take a statin drug in order to lower their blood cholesterol levels and supposedly prevent heart disease. The Centers for Disease Control (CDC) admit that statin drug use is on the rise; Atorvastatin (Lipitor) is the best-selling prescription drug in the world. The...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
(MedPage Today) -- Women, minorities, younger adults, older adults less likely to adhere
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
To investigate the effect of statins on relapse of Takayasu arteritis (TAK), which frequently occurs after achievement of remission.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
AbstractIntroductionFatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4  g/day as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia.MethodsThis was a prespecified exploratory subset analysis of the ANCHOR study, which randomized 702 statin-treated patients at increased cardiovascular risk with triglycerides 200 –...
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
rez-Rojop Juan C. Díaz-Zagoya We analyzed the effect of diosgenin, administered with atorvastatin or ezetimibe, on the fate of 3H(G)-taurocholic acid or 26-14C-cholesterol in hypercholesterolemic rats. Male Wistar rats received a hypercholesterolemic diet (HD), HD + atorvastatin (HD+ATV), HD + ezetimibe (HD+EZT), HD + diosgenin (HD+DG), HD+ATV+EZT, or HD+ATV+DG for 40 days. We also included a control normal group (ND). The labelled compounds were administered on day 30. The animals were placed in metabolic cages for daily feces collection. At day 40 the rats were sacrificed. Lipid extracts from blood, liver, s...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Better characterization of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) profile is currently needed to tailor appropriate lipid-lowering strategies in HIV patients.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
Conclusion: Of the 1.7 million participants, 1 in 10 had a high risk for CVD; among those at high risk, fewer than 3% were receiving statins or aspirin. An immense opportunity exists for risk mitigation in this substantial population. Primary Funding Source: Ministry of Finance and National Health Commission, China. PMID: 30776800 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
nández-Ahijado C PMID: 30776798 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
AbstractPurpose of ReviewTo provide an overview of recent pharmacological treatments for portal hypertension evaluated in early clinical trials, with particular emphasis on the pathophysiological basis of their use.Recent FindingsIn patients with compensated cirrhosis, even small decreases in portal pressure (as small as 1  mmHg) are associated with a lower probability of decompensation. In patients with decompensated cirrhosis, portal pressure “response” to non-selective beta-blocker (NSBB) therapy is associated with a lower mortality. When present, significant portal hypertension persists even after the ...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
More News: Cardiology | Cholesterol | Heart | Niacin | Niaspan | Statin Therapy | Vitamin B3